Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07323056 | Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer | recruiting | Phase 2 | 36 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06627738 | Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost(Cybertaxcis II) | recruiting | Phase 2 | 42 | Centre Antoine LacassagneOTHER | 1 | Jan 5, 2026 |
| clinicaltrials |
| NCT06903377 | Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 50 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07120698 | Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)(CTONG 2508) | recruiting | Phase 2 | 115 | Guangdong Association of Clinical TrialsOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06877299 | Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer | recruiting | Phase 2 | 30 | Sichuan UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06295432 | A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) | recruiting | Phase 2 | 90 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07073365 | Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)(BOOST) | recruiting | Phase 2 | 70 | Pusan National University HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07304739 | Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07117890 | Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations(WU-KONG35) | recruiting | Phase 2 | 34 | Fudan UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06512051 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 248 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07192068 | Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.(AcSé HER2) | recruiting | Phase 2 | 105 | UNICANCEROTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04966663 | Using ctDNA to Determine Therapies for Lung Cancer(ctDNA Lung RCT) | recruiting | Phase 2 | 66 | University Health Network, TorontoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06102057 | PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC(PACCELIO) | recruiting | Phase 2 | 110 | TheraOpOTHER | 2 | Dec 17, 2025 | clinicaltrials |
| NCT06121505 | Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer | recruiting | Phase 2 | 114 | Sichuan UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07169552 | HC010 in First-line PD-L1 Positive Advanced NSCLC Patients | recruiting | Phase 2 | 50 | HC Biopharma Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT07224971 | Impact of Circadian Rhythm on Immunotherapy | recruiting | Phase 2 | 350 | Liza Villaruz, MDOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06910761 | Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07264647 | Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 30 | Fondazione Ricerca TraslazionaleOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05751018 | Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 18 | Peking Union Medical College HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259226 | Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers(OASIS) | recruiting | Phase 2 | 400 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07229729 | A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer | recruiting | Phase 2 | 300 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07206498 | A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC(WAYWIN103) | recruiting | Phase 1 / Phase 2 | 48 | Wayshine Biopharm, Inc.INDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | recruiting | Phase 2 | 200 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07058519 | A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC | recruiting | Phase 2 | 250 | Shanghai Chest HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06652048 | High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI | recruiting | Phase 2 | 60 | Jialei WangOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06352008 | To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer | recruiting | Phase 2 | 64 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06496490 | A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality | recruiting | Phase 2 | 270 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06455917 | TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients(BaseTIL-02L) | recruiting | Phase 2 | 30 | University Hospital, Basel, SwitzerlandOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06917573 | PALACE: Cemiplimab Trial According to ctDNA Levels(PALACE) | recruiting | Phase 2 | 63 | Fundación GECPOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07153445 | Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)(ATHENEA) | recruiting | Phase 2 | 97 | Fundación GECPOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07175220 | Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects | recruiting | Phase 2 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06542159 | Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases | recruiting | Phase 2 | 130 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06582940 | Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis | recruiting | Phase 2 | 168 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06848699 | A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 105 | Shanghai Henlius BiotechINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07231068 | A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation | recruiting | Phase 1 / Phase 2 | 153 | Henan Genuine Biotech Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05558904 | An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer | recruiting | Phase 1 / Phase 2 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs(KYANITE-1) | recruiting | Phase 1 / Phase 2 | 250 | Krystal Biotech, Inc.INDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT01720836 | Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 30 | Olivera FinnOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT06305715 | Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X) | recruiting | Phase 2 | 34 | Medical College of WisconsinOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07181499 | Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI | recruiting | Phase 2 | 28 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198217 | Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient | recruiting | Phase 2 | 20 | Zibo Municipal HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05956587 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 121 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06623136 | A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 40 | Elpiscience (Suzhou) Biopharma, Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07193641 | A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC | recruiting | Phase 2 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 26, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 7, 2026source: clinicaltrials